TY - JOUR T1 - Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. JF - Cochrane Database Syst Rev Y1 - 2011 A1 - M. Arbyn A1 - L Xu A1 - Cindy Simoens A1 - Martin-Hirsch, Pierre Pl A1 - Bryant, Andrew A1 - Beutels, Philippe A1 - Paraskevaidis, Evangelos A1 - van Hoof, Elke A1 - Steben, Marc A1 - Qiao, Youlin A1 - Zhao, Fang-Hui A1 - Schneider, Achim A1 - Kaufmann, Andreas A1 - Dillner, Joakim A1 - Markowitz, Lauri A1 - Hildesheim, Allan KW - clinical efficacy KW - immunogenicity KW - prophylactic HPV vaccines AB -

This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the immunogenicity, clinical efficacy, and safety of prophylactic HPV vaccines in females. The assessment of clinical efficacy will address protection against HPV infection (for homologous and heterologous HPV types), against re-infection, against cervical cancer and its precursors (high-grade CIN (grade 2 or grade 3), adenocarcinoma in situ) in women previously not exposed to HPV infection (negative at enrolment for both HPV DNA and antibodies against the vaccine HPV types). We will assess clinical effectiveness by evaluating outcomes in all women, irrespective of the HPV DNA or serology status at enrolment. Evaluation by fine age and time since sexual debut categories is also planned.

VL - 2011 CP - 4 U1 - http://www.ncbi.nlm.nih.gov/pubmed/25267916?dopt=Abstract M3 - 10.1002/14651858.CD009069 ER -